Table 4.

Views with respect to pharmacovigilance, ADRs reporting, and factors that could improve ADRs reporting (one or multiple choices).

The usefulness of pharmacovigilance activities is to:	Total (532) no (%)	GP (169) no (%)	Non-GP (363)* no (%)
Measure the incidence of adverse effects;	313 (58.83)	94 (55.62)	219 (60.33)
Identify diseases for which the most commonly prescribed is a particular drug;	75 (14.10)	17 (10.06)	58 (15.98)
Identify factors that predispose to the occurrence of reactions (e.g., dose, age);	303 (56.95)	99 (58.58)	204 (56.20)
Identify new, unknown, rare, or bizarre adverse drug reactions;	328 (61.65)	91 (53.85)	237 (65.29)
Allow comparison of ADRs in the same therapeutic class;	199 (37.41)	56 (33.14)	143 (39.39)
Reduce the incidents occurring because of adverse drug reactions	376 (70.68)	121 (71.60)	255 (70.25)

Factors that might encourage voluntary reporting of adverse reactions (one or multiple choices)	Total (532) no (%)	GP (169) no (%)	non-GP (363)** no (%)
For each report feedback provided from NAMMD and/or marketing authorization holder;	201 (37.78)	69 (40.83)	132 (36.36)
Periodic inform physician about all adverse reactions reported and the measures taken;	321 (60.34)	114 (67.46)	207 (57.02)
Ease of reporting (e.g., online reporting);	364 (68.42)	110 (65.09)	254 (69.97)
Periodic training of medical staff on reporting utility	256 (48.12)	66 (39.05)	190 (52.34)
Monthly discussion of rare ADRs received by NMMDA.	124 (23.31)	37 (21.89)	87 (23.97)

Opinion about ADRs reporting:	Total (532) no (%)	GP (169) no (%)	non-GP (363)*** no (%)
Should be mandatory;	265 (49.81)	77 (45.56)	188 (51.79)
Should be voluntarily;	168 (31.58)	60 (35.50)	108 (29.75)
Should be optional and paid;	63 (11.84)	24 (14.20)	39 (10.74)
I do not know	25 (4.70)	6 (3.55)	19 (5.23)
No answer	6 (1.13)	1 (0.59)	5 (1.38)
Is useless;	5 (0.94)	1 (0.59)	4 (1.10)

x2 = 4.93; df = 5; p = 0.425;

** x2 = 7,46; df = 4; p = 0.114;

*** x2 = 4,92; df = 5; p = 0.426